CymaBay Therapeutics to commence Phase 2 study of MBX-8025 in primary biliary cholangitis

US-based clinical-stage biopharmaceutical company CymaBay Therapeutics announces its plans to initiate the next Phase 2 study of MBX-8025 in the subjects with primary biliary cholangitis (PBC).

Source: Drug Development Technology - October 6, 2016 Category: Pharmaceuticals Source Type: news